Budget 2026–27 announcement of "Biopharma Shakti" to catalyse India's global role in the next industrial revolution and also establish India as a global biomanufacturing hub: Dr. Jitendra Singh

1. At a Glance

• Biopharma SHAKTI = Strategy for Healthcare Advancement through Knowledge, Technology & Innovation — a ₹10,000-crore scheme announced in the Union Budget 2026–27 to make India a global biomanufacturing hub [S1][S3][S5].
• Pushes India "beyond conventional pharma" into the next industrial phase (biologics, biosimilars, precision biotherapeutics) and complements the BioE3 Policy, 2024 [S1][S6].
• Announced by MoS (IC) Science & Technology, Dr. Jitendra Singh; rides alongside Budget 2026-27 announcements on four mega-telescope facilities, ₹20,000-crore carbon-capture support, SHANTI Act nuclear duty alignment, and National Geospatial Mission [S1].

2. Why in the News

• Union Budget 2026–27 (1 Feb 2026) proposed Biopharma SHAKTI with a ₹10,000 crore outlay over 5 years [S1][S3][S5].
• Centre subsequently constituted an inter-ministerial panel headed by Manoj Joshi, Secretary, Department of Pharmaceuticals, to design & monitor the scheme [S3].

3. Background & Evolution

• 2022: India's bioeconomy crosses USD 100 bn; National Biotech Development Strategy lays groundwork.
• Aug 2024: Cabinet approves BioE3 Policy (Biotechnology for Economy, Environment & Employment) — parent framework for "high-performance biomanufacturing"; introduces BioEnablers = Bio-AI Hubs, Biofoundries, Biomanufacturing Hubs [S6].
• 2025: DBT–BIRAC joint call for मूलांकुर (Moolankur) Bioenablers proposals under BioE3 [S6].
• Feb 2026: Biopharma SHAKTI announced in Budget 2026-27 as a dedicated financial instrument operationalising the biologics arm of BioE3 [S1][S5].

4. Core Static Facts

• Full form: Strategy for Healthcare Advancement through Knowledge, Technology & Innovation [S5].
• Outlay: ₹10,000 crore over 5 years [S1][S3].
• Nodal ministries: Department of Pharmaceuticals (Ministry of Chemicals & Fertilizers) for SHAKTI implementation; aligned with Department of Biotechnology (Ministry of S&T) running BioE3 [S3][S6].
• Inter-ministerial panel chair: Secretary, Department of Pharmaceuticals (Manoj Joshi) [S3].
• Target market share: ~5% of the global biopharmaceutical market [S2].
• Key deliverables [S2][S3]:
• 3 new NIPERs + upgradation of 7 existing NIPERs.
• 1,000+ accredited clinical trial sites ("India Clinical Trials" network).
• CDSCO capacity-building via a dedicated scientific review cadre.
• Focus products: biologics, biosimilars, precision biotherapeutics (cell & gene therapy, mRNA, monoclonal antibodies) [S2][S6].
• India's current standing: among top-10 global bioeconomies, top-3 in Asia-Pacific [S2].

5. Multi-Dimensional Analysis

Economic - Scales domestic biologics manufacture to capture 5% of a market dominated by US/EU; reduces import dependence on high-value biosimilars [S2]. - Embeds India deeper into pharma global value chains (already the "pharmacy of the world" in generics) [S2].

Scientific / Technological - Bridges lab-to-market gap via biofoundries and Bio-AI hubs (BioE3) [S6]. - CDSCO modernisation aligns Indian approval timelines with US-FDA/EMA standards [S2].

Social / Health - 1,000-site clinical trial network broadens patient access and diversifies trial demographics [S2]. - Strengthens healthcare security post-COVID supply-shock lessons [S2].

Administrative / Governance - Inter-ministerial panel structure (DoP + DBT + MoHFW + DST) addresses traditional silo problem in biotech-pharma overlap [S3]. - Builds on public-private co-creation model of BioE3 [S6].

Environmental - BioE3 umbrella prioritises bio-based chemicals, biopolymers, carbon capture & utilisation — aligning biomanufacturing with net-zero (2070) goals [S6].

6. Recent Developments (last 12-18 months)

• Aug 2024: BioE3 Policy approved by Cabinet [S6].
• 2025: DBT–BIRAC Moolankur call for biofoundries/biomanufacturing hubs; Assam becomes first state to sign MoU with DBT under BioE3 [S6].
• 1 Feb 2026: Biopharma SHAKTI announced in Budget [S1].
• Feb–Mar 2026: Inter-ministerial panel constituted under Secretary, DoP, to operationalise scheme [S3].
• Companion Budget 2026-27 S&T pushes (Jitendra Singh): four mega telescopes (incl. National Large Solar Telescope, National Large Optical-Infrared Telescope); ₹20,000-crore carbon capture support; SHANTI Act–aligned nuclear import duty exemptions; National Geospatial Mission [S1].

7. Prelims Hooks

• Biopharma SHAKTI expands to Strategy for Healthcare Advancement through Knowledge, Technology and Innovation [S5].
• Outlay = ₹10,000 crore, duration 5 years, announced in Union Budget 2026-27 [S1][S3].
• Nodal implementing department: Department of Pharmaceuticals (not DBT) [S3].
• Inter-ministerial panel headed by Secretary, Department of Pharmaceuticals [S3].
• Scheme targets 5% share of global biopharma market [S2].
• Plans 3 new + 7 upgraded NIPERs [S2].
• Plans 1,000+ accredited clinical trial sites [S2].
• Strengthens CDSCO (regulator under Directorate General of Health Services, MoHFW) [S2].
• Parent policy: BioE3 Policy, approved by Cabinet in August 2024; full form: Biotechnology for Economy, Environment & Employment [S6].
• BioE3 BioEnablers = Bio-AI Hubs, Biofoundries, Biomanufacturing Hubs [S6].
• BioE3 thematic areas include smart proteins, mRNA therapeutics, marine & space biotech [S6].
• DBT–BIRAC call branded "मूलांकुर" (Moolankur) for Bioenablers [S6].
• India ranks among top 10 global bioeconomies, top 3 in Asia-Pacific [S2].
• Companion Budget 2026 science items: ₹20,000-crore carbon capture, SHANTI Act nuclear duty exemptions, National Geospatial Mission, National Large Solar Telescope [S1].

8. Mains Relevance

• GS-III: Science & Technology — developments and applications; Indian economy — issues of growth, employment; Government Budgeting.
• GS-II: Government schemes & welfare; Health sector governance.
• Probable stems: 1. "Biopharma SHAKTI complements but does not duplicate the BioE3 Policy." Discuss in light of India's ambition to be a global biomanufacturing hub. 2. Examine how regulatory modernisation (CDSCO, NIPERs, clinical trial sites) is central to translating biotechnology R&D into manufacturing scale in India. 3. India aspires to capture 5% of the global biopharma market by the early 2030s. Discuss the enabling ecosystem and the constraints.

9. Related Topics to Study Next

• BioE3 Policy, 2024 — direct parent framework [S6].
• PLI Scheme for Pharmaceuticals & Bulk Drugs — manufacturing complementarity.
• National Biotechnology Development Strategy (NBDS) — long-term policy spine.
• CDSCO & New Drugs and Clinical Trials Rules, 2019 — regulatory backbone.
• NIPERs (National Institutes of Pharmaceutical Education & Research) — human-capital arm.
• BIRAC (Biotechnology Industry Research Assistance Council) — funding vehicle.
• Genome India Programme — precision medicine linkage.
• SHANTI Act / National Geospatial Mission / Carbon Capture Mission — Budget 2026-27 S&T basket [S1].

10. Common Errors / Trap Areas

• Wrong ministry: Biopharma SHAKTI is implemented by Department of Pharmaceuticals, not DBT or MoHFW; DBT runs the parent BioE3 [S3][S6].
• Confusing the acronyms: BioE3 ≠ Biopharma SHAKTI; BioE3 (2024) is policy umbrella, SHAKTI (2026) is the budgetary scheme.
• Misreading "SHAKTI": Stands for Strategy for Healthcare Advancement through Knowledge, Technology & Innovation — not "Shakti" energy/electricity scheme [S5].
• CDSCO comes under Directorate General of Health Services, Ministry of Health & Family Welfare — not under Department of Pharmaceuticals.
• BioE3 was approved by Cabinet in August 2024, not in a Budget speech.

11. Sources

• [S1] Budget 2026–27 announcement of "Biopharma Shakti" … Dr. Jitendra Singh — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221778 — (tier 1)
• [S2] Transforming India into a Global Biopharma Hub — Budget 2026-27 Series, PIB — https://static.pib.gov.in/WriteReadData/specificdocs/documents/2026/feb/doc202622776701.pdf — (tier 1)
• [S3] Bio Pharma SHAKTI scheme (inter-ministerial panel), PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2237416 — (tier 1)
• [S4] Budget Push to Make India a Global Biopharma Hub, PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221492 — (tier 1)
• [S5] Biopharma SHAKTI proposed in Union Budget 2026-27, PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221443 — (tier 1)
• [S6] BioE3 Policy & Bioenablers (DBT/PIB) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2078063 ; https://bmi.dbtindia.gov.in/ — (tier 1)